多西他赛、奈达铂化疗联合三维适形调强放疗治疗食管癌术后复发的临床研究  

Clinical Study of Docetaxel+Nedaplatin Chemotherapy Combined with Three-dimensional Intensity Modulated Radiotherapy in the Treatment of Postoperative Recurrence of Esophageal Cancer

作　　者：刘凯[1] 黄莉[1] 李文婷[2] LIU Kai;HUANG Li;LI Wen-ting(Head and Neck Radiotherapy Department, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang 830011;Pathology Department, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang 830011)

机构地区：[1]新疆医科大学附属肿瘤医院头颈放疗科,830011 [2]新疆医科大学附属肿瘤医院病理科,830011

出　　处：《现代消化及介入诊疗》2020年第3期330-333,339,共5页Modern Interventional Diagnosis and Treatment in Gastroenterology

基　　金：新疆维吾尔自治区自然科学基金(2017D01C389)。

摘　　要：目的探讨食管癌术后复发患者经三维适形调强放疗联合多西他赛+奈达铂化疗治疗后的临床效果。方法选取新疆医科大学附属肿瘤医院2013年2月至2017年2月接收的97例食管癌术后复发患者,根据乱数表法随机分为对照组(48例)和研究组(49例)。对照组患者给予三维适形调强放疗治疗,研究组患者在对照组基础上联合多西他赛+奈达铂化疗。比较两组患者临床疗效、血清肿瘤标志物、生存率、不良反应。结果研究组临床总有效率为69.39%,明显高于对照组的47.92%(P<0.05)。两组治疗后血清细胞角蛋白21-1片段(CYFRA21-1)、鳞状细胞癌抗原(SCC)、癌胚抗原(CEA)水平均降低,且研究组显著低于对照组(P<0.05)。两组治疗期间不良反应总发生率比较无统计学差异(P>0.05)。研究组的1年生存率、2年生存率均高于对照组(P<0.05)。结论食管癌术后复发患者经三维适形调强放疗联合多西他赛+奈达铂同步化疗后,疗效确切,血清肿瘤标志物水平得到显著改善,患者生存率提高,且不增加不良反应发生率。Objective To investigate the clinical efficacy of docetaxel plus Nedaplatin Combined with three-dimensional conformal intensity modulated radiotherapy(IMRT)in the treatment of recurrent esophageal cancer.Methods 97 patients with recurrence of esophageal cancer who were admitted to our hospital from February 2013 to February 2017 were selected.All the subjects were randomly divided into control group(n=48)and study group(n=49).The control group was given three-dimensional conformal intensity modulated radiation therapy.The study group was combined with docetaxel+nedaplatin chemotherapy on the basis of the control group.The clinical efficacy,serum tumor markers,survival rate and adverse reactions of the two groups were compared.Results The total clinical effective rate of the study group was higher than that of the control group(P<0.05).After treatment,the levels of serum cytokeratin 21-1 fragment(CYFRA21-1),squamous cell carcinoma antigen(SCC),carcinoembryonic antigen(CEA)in both groups were decreased,and those in the study group were lower than those in the control group(P<0.05).The 1-year and 2-year survival rates of the study group were higher than those of the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Docetaxel plus Nedaplatin Combined with three-dimensional conformal intensity modulated radiation therapy can effectively improve the level of serum tumor markers,improve the survival rate of patients with esophageal cancer recurrence after operation,with definite curative effect,without increasing the incidence of adverse reactions,and has high clinical value.

关 键 词：多西他赛 奈达铂 三维适形调强放疗 食管癌 术后复发 临床研究 

分 类 号：R735.1[医药卫生—肿瘤] R571[医药卫生—临床医学]